Table 3.
n | HR (95% CI) | P value | |
---|---|---|---|
Patient characteristics | |||
Gender | |||
Male | 31 | 1.0 | 0.44 |
Female | 9 | 0.7 (0.3–1.7) | |
Race | |||
White | 30 | 1.0 | 0.77 |
Black | 6 | 0.9 (0.3–2.3) | |
Race | |||
White | 30 | 1.0 | 0.98 |
Other | 10 | 1.0 (0.5–2.2) | |
Age | 40 | 1.0 (0.9–1.0) | 0.28 |
Clinical measures | |||
Primary tumor site | |||
Non-OP | 24 | 1.0 | 0.74 |
OP | 16 | 0.9 (0.4–1.8) | |
Polymorphism | |||
FF | 14 | 1.0 | 0.82 |
FV or VV | 21 | 0.9 (0.4–1.9) | |
Surgery (in addition to treatment) | |||
No surgery | 14 | 1.0 | 0.86 |
Surgery | 25 | 0.9 (0.5–1.9) | |
P16 staining | |||
Negative | 7 | 1.0 | 0.09 |
Positive | 6 | 0.3 (0.1–1.2) | |
ADCC response | |||
No Response | 17 | 1.0 | 0.85 |
Response | 8 | 1.1 (0.4–2.9) |
Abbreviation: OP, oropharynx.
OS is defined from the date of start of treatment till the date of death or censored at the date last known alive.